Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study
Upregulation of programmed death ligand 1 (PD-L1) is a mechanism of immune escape utilized by a variety of tumors. PD-L1 expression in tumor cells or in the surrounding infiltrate correlates with clinical responsiveness to novel therapies targeting the PD-1/PD-L1 immune checkpoint. In the context of...
Main Authors: | Salvinia Mletzko, David J. Pinato, Rebecca C. Robey, Alessia Dalla Pria, Peter Benson, Nesrina Imami, Mark Bower |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-08-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2017.1304337 |
Similar Items
-
The T-Cell Immune Response against Kaposi's Sarcoma-Associated Herpesvirus
by: Rebecca C. Robey, et al.
Published: (2010-01-01) -
Kaposi’s Sarcoma Presenting as Lymphadenopathy in an Immunocompetent Patient
by: Hana Zoubeidi, et al.
Published: (2016-11-01) -
Recent advances in HIV-associated Kaposi sarcoma [version 1; peer review: 2 approved]
by: Alessia Dalla Pria, et al.
Published: (2019-06-01) -
Consequences of a Delayed Diagnosis of Kaposi’s Sarcoma: A Case Report of Disseminated Infection
by: Leonardo Henrique Bertolucci, et al.
Published: (2021-02-01) -
Global CpG DNA Methylation Footprint in Kaposi’s Sarcoma
by: Guy Journo, et al.
Published: (2021-07-01)